BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Psoriasis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for psoriasis: 184 (82 sponsors; 34 newly posted in the last 180 days, 4 stopped in the last 180 days; 14 new-entrant sponsors). Momentum score 26.6, rank 9 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 22, Phase 2 38, Phase 3 62, Phase 4 11, N/A 51.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Janssen Research & Development, LLC16P2 1, P3 11, P4 2, NA 212
Takeda TAK7P3 720
Bristol-Myers Squibb BMY16NA 10, P3 612
AbbVie ABBV12P3 4, NA 5, P2 2, P1 110
UCB Biopharma SRL5P3 3, P1 201
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.3P3 300
MoonLake Immunotherapeutics AG MLTX3P3 301
Sun Pharmaceutical Industries Limited3P3 300
InventisBio Co., Ltd4P3 2, P2 200
Suzhou Suncadia Biopharmaceuticals Co., Ltd.3P4 1, P3 201
Jiangsu HengRui Medicine Co., Ltd.4P2 2, P1 1, P3 101
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.3P3 1, P1 1, P2 110
Hansoh BioMedical R&D Company3P2 2, P3 112
Alumis Inc ALMS2P3 1, P2 100
Celltrion2NA 1, P3 101
CSPC Ouyi Pharmaceutical Co., Ltd.2P3 1, P2 101
SFA Therapeutics2P3 1, P1 100
Zhejiang Wenda Pharma Technology LTD.2P2 1, P3 111
Beijing InnoCare Pharma Tech Co., Ltd.1P3 100
Biocad1P3 100
Can-Fite BioPharma CANF1P3 100
Dermavon Holdings Limited1P3 100
Janssen Pharmaceutical K.K.1P3 100
Psoriasis Research Institute of Guangzhou1P3 100
Qilu Pharmaceutical Co., Ltd.1P3 100

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3Zhejiang Wenda Pharma Technology LTD.NCT07672561 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate toModerate to Severe Plaque Psoriasisrecruiting375
2026-12-20 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07158268 A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasisnot yet recruiting220
2026-12-31 est.P2Guangdong Hengrui Pharmaceutical Co., LtdNCT07719530 Phase II Clinical Trial of SHR-1139 Injection in Patients With PsoriasisPsoriasisrecruiting60
2027-01 est.P3Reistone Biopharma Company LimitedNCT07543224 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients WPlaque Psoriasis Subjectsnot yet recruiting600
2027-02 est.P2Clarent Biopharma, Inc.NCT07706530 Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)Arthritic Psoriasisnot yet recruiting240

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-12-12PDUFA date (company-disclosed)pendingANAPTYSBIO, INC ANABimsidolimabPDUFA Dec. 12, 2026 - ANAPTYSBIO, INC (imsidolimab)

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-06 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07150988 A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque PsoriasisPsoriasisnot yet recruiting150
2026-11 est.P3Wooshin Labottach Co., Ltd.NCT07029516 Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, PsoriasisNail Psoriasis; Nail Damage; Mycosisrecruiting72
2026-10-30P2Beijing InnoCare Pharma Tech Co., Ltd.NCT07251998 Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted182
2026-10-21P2Oruka Therapeutics, Inc. ORKANCT07290569 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisPlaque Psoriasisactive not recruiting160
2026-10-14P3Organon and Co OGNNCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsPlaque Psoriasiscompleted58
2026-09-30 est.P3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07265284 A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisPsoriasisrecruiting104
2026-08-12P3Amgen AMGNNCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisPlaque Psoriasiscompleted51
2026-08-06P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07357831 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsPlaque Psoriasiscompleted539
2026-07-31 est.P2Clarent Biopharma, Inc.NCT07204639 Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in SubjectsPsoriasisrecruiting100
2026-07-30P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisGeneralized Pustular Psoriasisterminated36
2026-07-21P3Bristol-Myers Squibb BMYNCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisPsoriasiscompleted1466
2026-07-09 est.P2Hansoh BioMedical R&D CompanyNCT06926582 A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque PsoriasisPsoriasisnot yet recruiting305
2026-07 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06833307 The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque PsoriasisChildren and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasisnot yet recruiting90
2026-06-07 est.P3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT06945107 A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyPlaque Psoriasisactive not recruiting308
2026-06-01 est.P2/P3SFA TherapeuticsNCT06863493 Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis PatientsPsoriasis (PsO)not yet recruiting125
2026-06 est.P3BiocadNCT06640517 Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisPlaque Psoriasisactive not recruiting140

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "psoriasis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.